INCYTE CORPORATION Revenue
INCYTE CORPORATION (INCY) reported Revenue of $1.27 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-04-28
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.27B, a 20.87% increase year-over-year.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.51B, a 27.84% increase year-over-year.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.37B, a 20.05% increase year-over-year.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $1.22B, a 16.46% increase year-over-year.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $5.14B, a 21.22% increase from fiscal 2024.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $4.24B, a 14.76% increase from fiscal 2023.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $3.70B, a 8.87% increase from fiscal 2022.
- INCYTE CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $3.39B, a 13.67% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.27B 10-Q · filed 2026-04-28 | $2.78B derived: sum of 2 quarters · filed 2026-04-28 | $4.15B derived: sum of 3 quarters · filed 2026-04-28 | $5.36B derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $1.51B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $2.87B derived: sum of 2 quarters · filed 2026-02-10 | $4.09B derived: sum of 3 quarters · filed 2026-02-10 | $5.14B 10-K · filed 2026-02-10 |
| 2025-09-30 | $1.37B 10-Q · filed 2025-10-28 | $2.58B derived: sum of 2 quarters · filed 2025-10-28 | $3.63B 10-Q · filed 2025-10-28 | $4.81B derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $1.22B 10-Q · filed 2025-07-29 | $2.27B 10-Q · filed 2025-07-29 | $3.45B derived: sum of 3 quarters · filed 2026-04-28 | $4.58B derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $1.05B 10-Q · filed 2026-04-28 | $2.23B derived: sum of 2 quarters · filed 2026-04-28 | $3.37B derived: sum of 3 quarters · filed 2026-04-28 | $4.41B derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $1.18B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $2.32B derived: sum of 2 quarters · filed 2026-02-10 | $3.36B derived: sum of 3 quarters · filed 2026-02-10 | $4.24B 10-K · filed 2026-02-10 |
| 2024-09-30 | $1.14B 10-Q · filed 2025-10-28 | $2.18B derived: sum of 2 quarters · filed 2025-10-28 | $3.06B 10-Q · filed 2025-10-28 | $4.08B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $1.04B 10-Q · filed 2025-07-29 | $1.92B 10-Q · filed 2025-07-29 | $2.94B derived: sum of 3 quarters · filed 2026-02-10 | $3.86B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $880.89M 10-Q · filed 2025-04-29 | $1.89B derived: sum of 2 quarters · filed 2026-02-10 | $2.81B derived: sum of 3 quarters · filed 2026-02-10 | $3.77B derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $1.01B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.93B derived: sum of 2 quarters · filed 2026-02-10 | $2.89B derived: sum of 3 quarters · filed 2026-02-10 | $3.70B 10-K · filed 2026-02-10 |
| 2023-09-30 | $919.02M 10-Q · filed 2024-10-29 | $1.87B derived: sum of 2 quarters · filed 2024-10-29 | $2.68B 10-Q · filed 2024-10-29 | $3.61B derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $954.61M 10-Q · filed 2024-07-30 | $1.76B 10-Q · filed 2024-07-30 | $2.69B derived: sum of 3 quarters · filed 2025-02-10 | $3.51B derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $808.67M 10-Q · filed 2024-04-30 | $1.74B derived: sum of 2 quarters · filed 2025-02-10 | $2.56B derived: sum of 3 quarters · filed 2025-02-10 | $3.47B derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $926.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $1.75B derived: sum of 2 quarters · filed 2025-02-10 | $2.66B derived: sum of 3 quarters · filed 2025-02-10 | $3.39B 10-K · filed 2025-02-10 |
| 2022-09-30 | $823.30M 10-Q · filed 2023-10-31 | $1.73B derived: sum of 2 quarters · filed 2023-10-31 | $2.47B 10-Q · filed 2023-10-31 | $3.33B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $911.40M 10-Q · filed 2023-08-01 | $1.64B 10-Q · filed 2023-08-01 | $2.51B derived: sum of 3 quarters · filed 2024-02-13 | $3.32B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $733.24M 10-Q · filed 2023-05-02 | $1.60B derived: sum of 2 quarters · filed 2024-02-13 | $2.41B derived: sum of 3 quarters · filed 2024-02-13 | $3.11B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $862.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $1.68B derived: sum of 2 quarters · filed 2024-02-13 | $2.38B derived: sum of 3 quarters · filed 2024-02-13 | $2.99B 10-K · filed 2024-02-13 |
| 2021-09-30 | $812.99M 10-Q · filed 2022-11-01 | $1.52B derived: sum of 2 quarters · filed 2022-11-01 | $2.12B 10-Q · filed 2022-11-01 | $2.91B derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $705.71M 10-Q · filed 2022-08-02 | $1.31B 10-Q · filed 2022-08-02 | $2.10B derived: sum of 3 quarters · filed 2022-08-02 | $2.72B derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $604.72M 10-Q · filed 2022-05-03 | $1.39B derived: sum of 2 quarters · filed 2022-05-03 | $2.01B derived: sum of 3 quarters · filed 2022-05-03 | $2.70B derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $789.51M 10-K · filed 2021-02-09 | $1.41B derived: sum of 2 quarters · filed 2021-11-02 | $2.10B derived: sum of 3 quarters · filed 2021-11-02 | $2.67B 10-K · filed 2023-02-07 |
| 2020-09-30 | $620.64M 10-Q · filed 2021-11-02 | $1.31B derived: sum of 2 quarters · filed 2021-11-02 | $1.88B 10-Q · filed 2021-11-02 | $2.46B derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $688.04M 10-Q · filed 2021-08-03 | $1.26B 10-Q · filed 2021-08-03 | $1.84B derived: sum of 3 quarters · filed 2021-08-03 | $2.39B derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $568.51M 10-Q · filed 2021-05-04 | $1.15B derived: sum of 2 quarters · filed 2021-05-04 | $1.70B derived: sum of 3 quarters · filed 2021-05-04 | $2.23B derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $579.39M 10-K · filed 2021-02-09 | $1.13B derived: sum of 2 quarters · filed 2021-02-09 | $1.66B derived: sum of 3 quarters · filed 2021-02-09 | $2.16B 10-K · filed 2022-02-08 |
| 2019-09-30 | $551.58M 10-K · filed 2021-02-09 | $1.08B derived: sum of 2 quarters · filed 2021-02-09 | $1.58B 10-Q · filed 2020-11-05 | $2.11B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $529.93M 10-K · filed 2021-02-09 | $1.03B 10-Q · filed 2020-08-04 | $1.56B derived: sum of 3 quarters · filed 2021-02-09 | $2.01B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $497.86M 10-K · filed 2021-02-09 | $1.03B derived: sum of 2 quarters · filed 2021-02-09 | $1.48B derived: sum of 3 quarters · filed 2021-02-09 | $2.00B derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $528.40M 10-K · filed 2020-02-13 | $978.09M derived: sum of 2 quarters · filed 2020-02-13 | $1.50B derived: sum of 3 quarters · filed 2020-02-13 | $1.88B 10-K · filed 2021-02-09 |
| 2018-09-30 | $449.68M 10-K · filed 2020-02-13 | $971.20M derived: sum of 2 quarters · filed 2020-02-13 | $1.35B 10-Q · filed 2019-10-29 | $1.80B derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $521.52M 10-K · filed 2020-02-13 | $903.80M 10-Q · filed 2019-07-30 | $1.35B derived: sum of 3 quarters · filed 2020-02-13 | $1.73B derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $382.28M 10-K · filed 2020-02-13 | $826.44M derived: sum of 2 quarters · filed 2020-02-13 | $1.21B derived: sum of 3 quarters · filed 2020-02-13 | $1.53B derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $444.16M 10-K · filed 2019-02-14 | $825.69M derived: sum of 2 quarters · filed 2019-02-14 | $1.15B derived: sum of 3 quarters · filed 2019-02-14 | $1.54B 10-K · filed 2020-02-13 |
| 2017-09-30 | $381.53M 10-K · filed 2019-02-14 | $707.98M derived: sum of 2 quarters · filed 2019-02-14 | $1.09B derived: sum of 3 quarters · filed 2019-02-14 | |
| 2017-06-30 | $326.44M 10-K · filed 2019-02-14 | $710.53M derived: sum of 2 quarters · filed 2019-02-14 | ||
| 2017-03-31 | $384.08M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |